JP Patent

JP4794816B2 — ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療

Assigned to ChemGenex Pharmaceuticals Pty Ltd · Expires 2011-10-19 · 15y expired

What this patent protects

Patent listed against Synribo.

Drugs covered by this patent

Patent Metadata

Patent number
JP4794816B2
Jurisdiction
JP
Classification
—
Expires
2011-10-19
Drug substance claim
No
Drug product claim
No
Assignee
ChemGenex Pharmaceuticals Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.